RU2010103781A - Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан - Google Patents
Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан Download PDFInfo
- Publication number
- RU2010103781A RU2010103781A RU2010103781/15A RU2010103781A RU2010103781A RU 2010103781 A RU2010103781 A RU 2010103781A RU 2010103781/15 A RU2010103781/15 A RU 2010103781/15A RU 2010103781 A RU2010103781 A RU 2010103781A RU 2010103781 A RU2010103781 A RU 2010103781A
- Authority
- RU
- Russia
- Prior art keywords
- irinotecan
- inhibitor
- vegf
- vegf inhibitor
- irinotekan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Комбинации, содержащие ингибитор VEGF с иринотеканом, терапевтически применяемые при лечении неопластических заболеваний. ! 2. Комбинации по п.1, содержащие ингибитор VEGF Trap с иринотеканом. ! 3. Комбинации по одному из пп.1 и 2, отличающиеся тем, что они содержат от 10% до 80 мас.% VEGF Trap. ! 4. Продукты, содержащие ингибитор VEGF и иринотекан, в лечении неопластических заболеваний как комбинированный препарат для одновременного, раздельного или распределенного во времени применения в противораковой терапии.
Claims (4)
1. Комбинации, содержащие ингибитор VEGF с иринотеканом, терапевтически применяемые при лечении неопластических заболеваний.
2. Комбинации по п.1, содержащие ингибитор VEGF Trap с иринотеканом.
3. Комбинации по одному из пп.1 и 2, отличающиеся тем, что они содержат от 10% до 80 мас.% VEGF Trap.
4. Продукты, содержащие ингибитор VEGF и иринотекан, в лечении неопластических заболеваний как комбинированный препарат для одновременного, раздельного или распределенного во времени применения в противораковой терапии.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0704868A FR2918279B1 (fr) | 2007-07-05 | 2007-07-05 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| FR0704868 | 2007-07-05 | ||
| PCT/FR2008/000943 WO2009024667A2 (fr) | 2007-07-05 | 2008-07-02 | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010103781A true RU2010103781A (ru) | 2011-08-10 |
| RU2471483C2 RU2471483C2 (ru) | 2013-01-10 |
Family
ID=38961256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010103781/15A RU2471483C2 (ru) | 2007-07-05 | 2008-07-02 | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20100160233A1 (ru) |
| EP (1) | EP2173349B1 (ru) |
| JP (4) | JP2010532335A (ru) |
| KR (4) | KR20150048910A (ru) |
| CN (3) | CN103623392A (ru) |
| AR (1) | AR067420A1 (ru) |
| AT (1) | ATE500829T1 (ru) |
| AU (1) | AU2008290442B2 (ru) |
| BR (1) | BRPI0812835B8 (ru) |
| CA (1) | CA2693152C (ru) |
| CY (1) | CY1111675T1 (ru) |
| DE (1) | DE602008005457D1 (ru) |
| DK (1) | DK2173349T3 (ru) |
| ES (1) | ES2362637T3 (ru) |
| FR (1) | FR2918279B1 (ru) |
| HR (1) | HRP20110432T1 (ru) |
| IL (2) | IL203132A (ru) |
| MX (1) | MX2009013950A (ru) |
| PL (1) | PL2173349T3 (ru) |
| PT (1) | PT2173349E (ru) |
| RS (1) | RS51777B (ru) |
| RU (1) | RU2471483C2 (ru) |
| SI (1) | SI2173349T1 (ru) |
| WO (1) | WO2009024667A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05002444A (es) | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
| JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス， インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
| US20110223241A1 (en) * | 2008-10-16 | 2011-09-15 | Celator Pharmaceuticals, Inc. | Combination methods and compositions |
| ES2354922B1 (es) | 2009-09-02 | 2012-02-07 | Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron | Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer. |
| US20130029909A1 (en) * | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
| SG10201802789VA (en) | 2011-01-13 | 2018-05-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
| JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60019415T2 (de) * | 1999-06-08 | 2006-03-09 | Regeneron Pharmaceuticals, Inc. | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
| IL163820A0 (en) * | 2002-03-01 | 2005-12-18 | Pharmacia Italia Spa | Crystalline polymorphic form of irinotecan hydrochloride |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US20050112061A1 (en) * | 2003-08-06 | 2005-05-26 | Jocelyn Holash | Use of a VEGF antagonist in combination with radiation therapy |
| CN1968709A (zh) * | 2004-06-18 | 2007-05-23 | 瑞泽恩制药公司 | 用于治疗恶性胸腔积液的vegf抑制剂 |
| FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
-
2007
- 2007-07-05 FR FR0704868A patent/FR2918279B1/fr active Active
-
2008
- 2008-07-02 RU RU2010103781/15A patent/RU2471483C2/ru active Protection Beyond IP Right Term
- 2008-07-02 DE DE602008005457T patent/DE602008005457D1/de active Active
- 2008-07-02 SI SI200830256T patent/SI2173349T1/sl unknown
- 2008-07-02 CN CN201310556556.4A patent/CN103623392A/zh active Pending
- 2008-07-02 CN CN200880023537A patent/CN101686975A/zh active Pending
- 2008-07-02 PT PT08827826T patent/PT2173349E/pt unknown
- 2008-07-02 ES ES08827826T patent/ES2362637T3/es active Active
- 2008-07-02 KR KR1020157010064A patent/KR20150048910A/ko not_active Application Discontinuation
- 2008-07-02 KR KR1020167017056A patent/KR20160079918A/ko not_active Application Discontinuation
- 2008-07-02 CN CN201610141168.3A patent/CN105833244A/zh active Pending
- 2008-07-02 PL PL08827826T patent/PL2173349T3/pl unknown
- 2008-07-02 AT AT08827826T patent/ATE500829T1/de active
- 2008-07-02 AU AU2008290442A patent/AU2008290442B2/en active Active
- 2008-07-02 DK DK08827826.2T patent/DK2173349T3/da active
- 2008-07-02 MX MX2009013950A patent/MX2009013950A/es active IP Right Grant
- 2008-07-02 JP JP2010514042A patent/JP2010532335A/ja active Pending
- 2008-07-02 CA CA2693152A patent/CA2693152C/fr not_active Expired - Fee Related
- 2008-07-02 EP EP08827826A patent/EP2173349B1/fr active Active
- 2008-07-02 WO PCT/FR2008/000943 patent/WO2009024667A2/fr active Application Filing
- 2008-07-02 RS RS20110215A patent/RS51777B/en unknown
- 2008-07-02 KR KR1020187026491A patent/KR20180105261A/ko not_active Application Discontinuation
- 2008-07-02 KR KR1020107000011A patent/KR20100031123A/ko not_active Application Discontinuation
- 2008-07-02 BR BRPI0812835A patent/BRPI0812835B8/pt active IP Right Grant
- 2008-07-04 AR ARP080102894A patent/AR067420A1/es not_active Application Discontinuation
-
2010
- 2010-01-04 IL IL203132A patent/IL203132A/en active IP Right Grant
- 2010-01-04 US US12/651,767 patent/US20100160233A1/en not_active Abandoned
-
2011
- 2011-06-08 CY CY20111100551T patent/CY1111675T1/el unknown
- 2011-06-09 HR HR20110432T patent/HRP20110432T1/hr unknown
-
2014
- 2014-01-13 US US14/153,795 patent/US20140127202A1/en not_active Abandoned
- 2014-08-29 JP JP2014174963A patent/JP2014240422A/ja active Pending
-
2015
- 2015-08-31 IL IL240965A patent/IL240965A0/en unknown
-
2016
- 2016-11-16 JP JP2016222826A patent/JP2017052789A/ja active Pending
-
2018
- 2018-08-15 JP JP2018152805A patent/JP2019006785A/ja active Pending
-
2019
- 2019-02-11 US US16/272,315 patent/US20190275147A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010103781A (ru) | Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| CY1120457T1 (el) | Αντι-ιικη θεραπεια | |
| WO2019032662A8 (en) | Clec9a binding agents and use thereof | |
| EP3173092A3 (en) | Rna containing composition for treatment of tumor diseases | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| UY33479A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento | |
| AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| EA201070544A1 (ru) | Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений | |
| ECSP109889A (es) | Composiciones terapeuticas y usos de las mismas | |
| MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| EA201491532A1 (ru) | Фармацевтические композиции для использования в комплексной терапии | |
| AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab | |
| BRPI0509667A (pt) | azaquinazolinas substituìdas com eficácia antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Free format text: CLAIMS: 1-3 Extension date: 20290715 |